Evidence map›Paper›PMID 29311295›Full record

Trial reportProceedings of the National Academy of Sciences of the United States of America2018

Demetrios G Vavvas, Kent W Small, Carl C Awh, Brent W Zanke, Robert J Tibshirani, Rafal Kustra

Open access · bronzeAbstract readClinical TrialValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. How do genetic polymorphisms influence the efficacy of age-related macular degeneration treatments? A systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Association ofInternational journal of ophthalmology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Demetrios G VavvasDepartment of Ophthalmology Retina Service, Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA 02114.
Kent W SmallMacula and Retina Institute, Los Angeles, CA 90048.
Carl C AwhTennessee Retina, Nashville, TN 37203.
Brent W ZankeDepartment of Medical Affairs, Arctic Medical Laboratories, Grand Rapids, MI 49504.
Robert J TibshiraniDepartment of Biomedical Data Science, Stanford University, Stanford, CA 94305; tibs@stanford.edu.
Rafal KustraDalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Harvard University · USMacula and Retina Institute · USStanford University · USTennessee Retina · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the influence of an antioxidant and zinc nutritional supplement [the Age-Related Eye Disease Study (AREDS) formulation] on delaying or preventing progression to neovascular AMD (NV) in persons with age-related macular degeneration (AMD). AREDS subjects (

Indexed as

AntioxidantsComplement Factor HDisease ProgressionHumansMacular DegenerationProteinsZincAntioxidantsARMS2 protein, humanCFH protein, humanComplement Factor HProteinsZincbootstrap validationgenetic effect modificationmacular degenerationophthalmologystatistical interaction

Identifiers

PMID29311295
PMCPMC5789949
OpenAlexW2782610741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.